Quick Answer
COGNITION THERAPEUTICS INC reported Diluted EPS of $0.32 per share (loss) for fiscal year 2025.
COGNITION THERAPEUTICS INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.32 | +62.8% |
| 2024 | -$0.86 | +0.0% |
| 2023 | -$0.86 | +5.5% |
| 2022 | -$0.91 | +70.9% |
| 2021 | -$3.13 | +86.8% |
| 2020 | -$23.76 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.06 | +76.0% | +45.5% |
| June 30, 2025 | -$0.11 | +38.9% | +21.4% |
| March 31, 2025 | -$0.14 | +48.1% | +44.0% |
| September 30, 2024 | -$0.25 | -13.6% | -38.9% |
| June 30, 2024 | -$0.18 | -12.5% | +33.3% |
| March 31, 2024 | -$0.27 | -28.6% | -22.7% |
| September 30, 2023 | -$0.22 | +24.1% | -37.5% |
| June 30, 2023 | -$0.16 | +36.0% | +23.8% |
- COGNITION THERAPEUTICS INC showed an increase of +62.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, COGNITION THERAPEUTICS INC’s diluted eps has grown by 98.7% (from $23.76 per share (loss) to $0.32 per share (loss)).
- The most recent figure is from COGNITION THERAPEUTICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: